Answers are grounded in this paper and cite their sources.
The objective of this study is to evaluate the safety and efficacy of neoadjuvant degarelix acetate and low-dose estramustine phosphate for high-/very high-risk prostate cancer.
No takes yet. Share an insight, caveat, or question.
Kambe et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: